Safety, efficacy, PK and PD biomarker results of the first-in-human study of mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor BAY 1436032 in patients (pts) with mIDH1 advanced solid tumours

Saved in:
Bibliographic Details
Published inAnnals of oncology Vol. 30; pp. v170 - v171
Main Authors Wick, W., Tabatabai, G., Schuler, M., Rorhberg, K., Chawla, S.P., Janku, F., Schiff, D., Heinemann, V., Narita, Y., Ando, Y., Lenz, H.J., Ikeda, M., Genvresse, I., Rentzsch, C., Reschke, S., Cyris, C., Cai, C., Jeffers, M., Peña, C., Bähr, O.
Format Journal Article
LanguageEnglish
Published 01.10.2019
Online AccessGet full text

Cover

More Information
ISSN:0923-7534
DOI:10.1093/annonc/mdz244.020